Loading
BCMA is a survival receptor on plasma cells, and the target that made CAR-T and bispecifics work in multiple myeloma. This dossier gathers the 14 products (8 approved), 59 trials, 0 pathways and 3 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
BCMA is a TNF receptor family member with APRIL and BAFF as ligands. Soluble BCMA can act as a decoy.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Multiple myeloma | >95% | Plasma-cell surface expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved | Phase 3 | Phase 2 | Phase 1 |
|---|---|---|---|---|
| Cell therapy 9 | - | |||
| T-cell engager 4 | - | - | ||
| ADC 1 | - | - | - |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Active | A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8) | - | ||
| 3 | Active | DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma | - | ||
| 3 | Active | DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma | - | ||
MajesTEC-3 NCT05083169 | 3 | Positive | Relapsed/refractory myeloma after 1-3 prior lines: teclistamab + daratumumab vs Dara-Pd or Dara-Vd | 36-month PFS 83.4% vs 29.7%; HR ~0.17. | |
DREAMM-7 NCT04246047 | 3 | Positive | Relapsed myeloma after ≥1 line: belantamab-Vd vs Dara-Vd | PFS 36.6 vs 13.4 months, HR 0.41; OS HR 0.58. | |
DREAMM-8 NCT04484623 | 3 | Positive | Relapsed myeloma after ≥1 line including lenalidomide: belantamab-Pd vs Pom-Vd | PFS HR 0.52. | |
CARTITUDE-4 NCT04181827 | 3 | Positive | Lenalidomide-refractory myeloma after 1-3 prior lines: cilta-cel vs Pom-Vd or Dara-Pd | PFS HR 0.26; OS HR 0.55. | |
KarMMa-3 NCT03651128 | 3 | Positive | Triple-class-exposed myeloma after 2-4 prior lines: ide-cel vs standard regimens | PFS 13.3 vs 4.4 months, HR 0.49. | |
| 3 | Active | A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3) | - | ||
| 3 | Recruiting | A Phase III Randomized, Controlled Study of Equecabtagene Autoleucel Injection in Subjects With Lenalidomide-Refractory R/R Multiple Myeloma | - | ||
| 3 | Active | A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma | - | ||
| 3 | Active | 64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom | - | ||
| 3 | Active | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide | - | ||
| 3 | Recruiting | A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | - | ||
| 3 | Recruiting | A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy | - | ||
| 3 | Recruiting | A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma | - | ||
| 3 | Active | A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9) | - | ||
| 3 | Recruiting | AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA | - | ||
| 3 | Recruiting | AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR | - | ||
| 3 | Recruiting | An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3) | - | ||
CARTITUDE-5 NCT04923893 | 3 | Active | Newly diagnosed myeloma, transplant not planned: VRd → cilta-cel vs VRd → Rd | - | |
CARTITUDE-6 NCT05257083 | 3 | Active | Transplant-eligible newly diagnosed multiple myeloma: daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by ciltacabtagene autoleucel CAR-T against DVRd followed by autologous stem cell transplant | - | |
| 3 | Recruiting | A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY | - | ||
| 3 | Active | A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION | - | ||
iMMagine-1 NCT05396885 | 2 | Positive | Relapsed/refractory myeloma after ≥4 lines: anito-cel single infusion | ORR 97%. | |
MagnetisMM-3 NCT04649359 | 2 | Positive | Relapsed/refractory myeloma after ≥3 lines, BCMA-naive: elranatamab monotherapy | ORR 61%. | |
| 2 | Recruiting | Phase 2 Dose-Ranging and Interception Study of Linvoseltamab in Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma | - | ||
| 2 | Active | Phase 2 Study of Linvoseltamab in Patients With Smoldering Multiple Myeloma at High Risk of Progression to Multiple Myeloma | - | ||
| 2 | Active | A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma | - | ||
| 2 | Active | A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma | - |
Deletion or mutation removes or alters the epitope; more common after bispecifics than CAR-T.
Prior lines, high tumour burden, and continuous bispecific dosing exhaust T cells; CAR-T products from heavily pretreated patients expand poorly.
Shed BCMA binds drug in circulation.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
| Cell line | Identifiers | Why it is used |
|---|---|---|
| MM.1S | CVCL_8792 · ACH-000763 | BCMA-high; luciferase derivatives for in vivo CAR-T imaging. |
| NCI-H929 | CVCL_1600 · ACH-000050 | BCMA-positive. |
| RPMI 8226 | CVCL_0014 · ACH-000817 | BCMA-positive. |
| U266 | CVCL_0566 · ACH-000626 | BCMA-lower comparator. |
| KMS-11 | CVCL_2989 · ACH-000714 | BCMA-positive; BCMA knock-out derivatives model antigen loss. |
Why unresolved. CARTITUDE-4 and MajesTEC data cover single lines; biallelic TNFRSF17 loss after bispecifics is described and T-cell fitness falls with each line, so sequencing changes outcomes in ways no trial has compared.
What would answer it. Randomised sequencing trials and registries capturing BCMA and GPRC5D expression and T-cell fitness at each switch.
Query for this target: (TITLE:"BCMA" OR ABSTRACT:"BCMA" OR TITLE:"TNFRSF17" OR ABSTRACT:"TNFRSF17") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BCMA, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/bcma.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/bcma.json. Licence CC BY-NC 4.0.